In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization

Respiratory Care

Volumn 55, Issue 12, 2010, Pages 1671-1679

  Berlinski, Ariel ^a   Willis, J Randy ^a   Leisenring, Tom ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Aerosol; Albuterol; Nebulization; Nebulizer; Particle size

Indexed keywords

SALBUTAMOL SULFATE;

AEROSOL; ARTICLE; ASTHMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; IN VITRO STUDY; INTERMETHOD COMPARISON; NEBULIZATION; NEBULIZER; PARTICLE SIZE; TEMPERATURE;

AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; DISPOSABLE EQUIPMENT; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; MATERIALS TESTING; NEBULIZERS AND VAPORIZERS;

EID: 78650325850     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma summary report 2007. J Allergy Clin Immunol 2007;120 (5 Suppl):S94-S138.
2. Erratum in: J Allergy Clin Immunol 2008;121(6): 1330.
3. Marcoux KK. Current management of status asthmaticus in the pediatric ICU. Crit Care Nurs Clin North Am 2005;17(4):463-479.
4. Craig VL, Bigos D, Brilli RJ. Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Pediatr Emerg Care 1996;12(1):1-5.
5. Reisner C, Kotch A, Dworkin G. Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. Ann Allergy Asthma Immunol 1995;75(1):41-47.
6. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993;21(10):1479-1486.
7. Carroll CL and Zucker AR. The increased cost of complications in children with status asthmaticus. Pediatr Pulmonol 2007;(42):914-919.
8. Voss KR, Willsie-Ediger SK, Pyszczynski DR, Nelson KA. Description of a delivery method for continuously aerosolized albuterol in status asthmaticus. J Asthma 1990;27:37-39.
9. Colacone A, Wolkove N, Stern E, Afilalo M, Rosenthal TM, Kreisman H. Continuous nebulization of albuterol (salbutamol) in acute asthma. Chest 1990;97(3):693-697.
10. Berlinski A, Waldrep JC. Four hours of continuous albuterol nebulization. Chest 1998;114(3):847-853.
11. McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. Chest 1997;111(5):1200-1205.
12. Raabe OG, Wong TM, Wong GB, Roxburgh JW, Piper SD, Lee JI. Continuous nebulization therapy for asthma with aerosols of ß2 agonists. Ann Allergy Asthma Immunol 1998;80(6):499-508.
13. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498-505.
14. Marple VA, Olson BA, Santhanakrishnan K, Roberts DL, Mitchell JP, Hudson-Curtis BL. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III: Extension of archival calibration to 15 L/min. J Aerosol Med 2004;17(4):335-343.
15. Berg E, Svensson JO, Asking L. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aerosol Med 2007;20(2):97-104.
16. Dennis J, Berg E, Sandell D, Ali A, Lamb P, Tservistas M, et al. Cooling the NGI - an approach to size a nebulised aerosol more accurately. Pharmeur Sci Notes 2008;(1):27-30.
17. United States pharmacopeia. Physical tests and determinations. In: United States pharmacopeia-national formulary (USP-NF 28). Rockville, MD: United States Pharmacopeia; 2004:2359-2377.
18. Preparations for nebulization: characterization. PharmEuropa 2006; 18(2):280-283.
19. Tandon R, McPeck M, Smaldone GC. Measuring nebulizer output: aerosol production vs gravimetric analysis. Chest 1997;111(5):1361-1365.
20. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997;52(Suppl 2):S31-S44.
21. Meyer RJ. Bringing new nebulizer technologies to market: regulatory issues. Respir Care 2002;47(11):1334-1336.
22. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of ß2-agonist particle size. Am J Respir Crit Care Med 2005;172(12):1497-504.
23. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 2003;95(5): 2106-2112.
24. Zanen P, Go LT, Lammers JWJ. Optimal particle size for β2- agonists and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996;51(10):977-980.
25. Kallergis EM, Manios EG, Kanoupanis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005;127(6):2057-2063.
26. Koskela HO, Purokivi MK, Kontra KM, Taivainen AH, Tukiainen HO. Hypertonic saline cough provocation test with salbutamol pretreatment: evidence for sensorineural dysfunction in asthma. Clin Exp Allergy 2008;38(7):1100-1107.
27. Delvaux M, Henket M, Lau L, Kange P, Bartsch P, Djukanovic R, Louis R. Nebulized salbutamol administered during sputum induction improves bronchoprotection in patients with asthma. Thorax 2004;59(2):111-115.
28. Reisner C, Lee J, Kotch A, Dworkin G. Comparison of volume output from two different continuous nebulizer systems. Ann Allergy Asthma Immunol 1996;76(2):209-213.
29. Hollie MC, Malone RA, Skufca RM, and Nelson HS. Extreme variability in aerosol output of the DeVilbiss 646 jet nebulizer. Chest 1991;100(5):1339-1344.
30. Alvine GF, Rodgers P, Fitzsimmons KM, and Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest 1992;101(2):316-319.
31. Phipps PR, and Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 1990;97(6):1327-1332.